Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 57, Issue 4, 2013, Pages 352-366

  Gaeta, C M ^a   Vercher Conejero, J L ^a   Sher, A C ^a   Kohan, A ^a   Rubbert, C ^a   Avril, N ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast neoplasms; Fluorodeoxyglucose F18; Magnetic resonance imaging; Medication therapy management; Neoplasm staging; Positron emission tomography

Indexed keywords

3' FLUOROTHYMIDINE F 18; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; INTEGRIN; TRASTUZUMAB;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; CELL PROLIFERATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HUMAN; LUNG METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOLYSIS; POSITRON EMISSION TOMOGRAPHY; REVIEW; TREATMENT RESPONSE;

EID: 84891621531     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-403.
2. National Cancer Institute. SEER Stat Fact Sheets: Breast. [Internet]. Available at http://seer.cancer.gov/statfacts/html/breast.html [cited on Sep 9, 2013].
3. Cardoso F, Bischoff J, Brain E, Zotano AG, Luck HJ, Tjan-Heijnen VC et al. A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women. Cancer Treat Rev 2013;39:457-65.
4. Grunt TW, Mariani GL. Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling. Curr Cancer Drug Targets 2013;13:188-204.
5. Cortes J, Calvo V, Ramirez-Merino N, O'Shaughnessy J, Brufsky A, Robert N et al. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann Oncol 2012;23:1130-7.
6. Carpenter D, Kesselheim AS, Joffe S. Reputation and precedent in the bevacizumab decision. N Engl J Med 2011;365;e3.
7. Bear HD, Tang G, Rastogi P, Geyer CE, Jr., Robidoux A, Atkins JN et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012;366:310-20.
8. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy- D-glucose. Radiology 1991;179:765-70.
9. Greco M, Crippa F, Agresti R, Seregni E, Gerali A, Giovanazzi R et al. Axillary Lymph Node Staging in Breast Cancer by 2-Fluoro-2-deoxy-D-glucose- Positron Emission Tomography: Clinical Evaluation and Alternative Management. J Natl Cancer Inst 2001;93:630-5. (Pubitemid 32409630)
10. Avril N, Dose J, Janicke F, Bense S, Ziegler S, Laubenbacher C et al. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996;14:1848-57. (Pubitemid 26185460)
11. Wahl RL, Siegel BA, Coleman RE, Gatsonis CG. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004;22:277-85. (Pubitemid 41095092)
12. Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997;349:1864-7. (Pubitemid 27270119)
13. Riegger C, Koeninger A, Hartung V, Otterbach F, Kimmig R, Forsting M et al. Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients. Acta Radiol 2012;53:1092-8.
14. Aukema TS, Straver ME, Peeters MJ, Russell NS, Gilhuijs KG, Vogel WV et al. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer. Eur J Cancer 2010;46:3205-10.
15. Constantinidou A, Martin A, Sharma B, Johnston SR. Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital. Ann Oncol 2011;22:307-14.
16. Dose J, Bleckmann C, Bachmann S, Bohuslavizki KH, Berger J, Jenicke L et al. Comparison of fluorodeoxyglucose positron emission tomography and "conventional diagnostic procedures" for the detection of distant metastases in breast cancer patients. Nucl Med Commun 2002;23:857-64.
17. Gallowitsch HJ, Kresnik E, Gasser J, Kumnig G, Igerc I, Mikosch P et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol 2003;38:250-6. (Pubitemid 36535030)
18. Siggelkow W, Zimny M, Faridi A, Petzold K, Buell U, Rath W. The value of positron emission tomography in the follow-up for breast cancer. Anticancer Res 2003;23:1859-67. (Pubitemid 36750859)
19. Eubank WB, Mankoff D, Bhattacharya M, Gralow J, Linden H, Ellis G et al. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. AJR Am J Roentgenol 2004;183:479-86. (Pubitemid 38970344)
20. Santiago JF, Gonen M, Yeung H, Macapinlac H, Larson S. A retrospective analysis of the impact of 18F-FDG PET scans on clinical management of 133 breast cancer patients. Q J Nucl Med Mol Imaging 2006;50:61-7.
21. van der Hoeven JJ, Krak NC, Hoekstra OS, Comans EF, Boom RP, van Geldere D et al. 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol 2004;22:1253-9. (Pubitemid 41079839)
22. Port ER, Yeung H, Gonen M, Liberman L, Caravelli J, Borgen P et al. 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography scanning affects surgical management in selected patients with high-risk, operable breast carcinoma. Ann Surg Oncol 2006;13:677-84.
23. Eubank WB, Mankoff DA, Takasugi J, Vesselle H, Eary JF, Shanley TJ et al. 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 2001;19:3516-23. (Pubitemid 32730089)
24. Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 2006;33:254-62.
25. Veit-Haibach P, Antoch G, Beyer T, Stergar H, Schleucher R, Hauth EA et al. FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy. Br J Radiol 2007;80:508-15.
26. Manohar K, Mittal BR, Senthil R, Kashyap R, Bhattacharya A, Singh G. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma. Nucl Med Commun 2012;33:591-6.
27. Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005;90:105-12. (Pubitemid 40568893)
28. Pan L, Han Y, Sun X, Liu J, Gang H. FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: a meta-analysis. J Cancer Res Clin Oncol 2010;136:1007-22.
29. Hong S, Li J, Wang S. (18)FDG PET-CT for diagnosis of distant metastases in breast cancer patients. A meta-analysis. Surg Oncol 2013;22:139-43.
30. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008;49:480-508. (Pubitemid 351355215)
31. Hodgson NC, Gulenchyn KY. Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol 2008;26:712-20. (Pubitemid 351264383)
32. Morris PG, Lynch C, Feeney JN, Patil S, Howard J, Larson SM et al. Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. J Clin Oncol 2010;28:3154-9.
33. Ohta M, Tokuda Y, Suzuki Y, Kubota M, Makuuchi H, Tajima T et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun 2001;22:875-9. (Pubitemid 32681625)
34. Peterson JJ, Kransdorf MJ, O'Connor MI. Diagnosis of occult bone metastases: positron emission tomography. Clin Orthop Relat Res 2003:S120-8. (Pubitemid 37323328)
35. Fujimoto R, Higashi T, Nakamoto Y, Hara T, Lyshchik A, Ishizu K et al. Diagnostic accuracy of bone metastases detection in cancer patients: comparison between bone scintigraphy and whole-body FDG-PET. Ann Nucl Med 2006;20:399-408. (Pubitemid 44259805)
36. Abe K, Sasaki M, Kuwabara Y, Koga H, Baba S, Hayashi K et al. Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med 2005;19:573-9. (Pubitemid 43161842)
37. Doot RK, Muzi M, Peterson LM, Schubert EK, Gralow JR, Specht JM et al. Kinetic analysis of 18F-fluoride PET images of breast cancer bone metastases. J Nucl Med 2010;51:521-7.
38. Piccardo A, Altrinetti V, Bacigalupo L, Puntoni M, Biscaldi E, Gozza A et al. Detection of metastatic bone lesions in breast cancer patients: fused (18)F-Fluoride-PET/MDCT has higher accuracy than MDCT. Preliminary experience. Eur J Radiol 2012;81:2632-8.
39. Withofs N, Grayet B, Tancredi T, Rorive A, Mella C, Giacomelli F et al. (1)(8)F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun 2011;32:168-76.
40. Iagaru A, Mittra E, Yaghoubi SS, Dick DW, Quon A, Goris ML et al. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. J Nucl Med 2009;50:501-5.
41. Iagaru A, Mittra E, Mosci C, Dick DW, Sathekge M, Prakash V et al. Combined 18F-fluoride and 18F-FDG PET/CT scanning for evaluation of malignancy: results of an international multicenter trial. J Nucl Med 2013;54:176-83.
42. Yap CS, Seltzer MA, Schiepers C, Gambhir SS, Rao J, Phelps ME et al. Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective. J Nucl Med 2001;42:1334-7. (Pubitemid 32852607)
43. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
44. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
45. Avril N, Sassen S, Roylance R. Response to therapy in breast cancer. J Nucl Med 2009;50 Suppl 1:55S-63S.
46. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773-82. (Pubitemid 29512308)
47. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009;50 Suppl 1:122S-50S.
48. Huyge V, Garcia C, Alexiou J, Ameye L, Vanderlinden B, Lemort M et al. Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients. Clin Biol (R Coll Radiol) 2010;22:818-27.
49. Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Janicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 2005;46:1144-50. (Pubitemid 43741076)
50. Gennari A, Donati S, Salvadori B, Giorgetti A, Salvadori PA, Sorace O et al. Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clin Breast Cancer 2000;1:156-61; discussion 162-3.
51. Mortazavi-Jehanno N, Giraudet AL, Champion L, Lerebours F, Le Stanc E, Edeline V et al. Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 2012;39:450-60.
52. Dehdashti F, Mortimer JE, Trinkaus K, Naughton MJ, Ellis M, Katzenellenbogen JA et al. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor- positive breast cancer. Breast Cancer Res Treat 2009;113:509-17.
53. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Biol 2001;19:2797-803. (Pubitemid 32538187)
54. Kostakoglu L, Goldsmith SJ. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 2003;44:224-39.
55. Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Macapinlac HA. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology 2008;247:189-96.
56. Network NCC: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)®, Breast Cancer, Version 2.2013, 2013
57. Iagaru A, Masamed R, Keesara S, Conti PS. Breast MRI and 18F FDG PET/CT in the management of breast cancer. Ann Nucl Med 2007;21:33-8. (Pubitemid 46280147)
58. Rieber A, Schirrmeister H, Gabelmann A, Nuessle K, Reske S, Kreienberg R et al. Pre-operative staging of invasive breast cancer with MR mammography and/or PET: boon or bunk? Br J Radiol 2002;75:789-98. (Pubitemid 35252005)
59. Lehman CD, Schnall MD. Imaging in breast cancer: magnetic resonance imaging. Breast Cancer Res 2005;7:215-9. (Pubitemid 41387434)
60. Goerres GW, Michel SC, Fehr MK, Kaim AH, Steinert HC, Seifert B et al. Follow-up of women with breast cancer: comparison between MRI and FDG PET. Eur Radiol 2003;13:1635-44. (Pubitemid 36869357)
61. Schmidt GP, Baur-Melnyk A, Herzog P, Schmid R, Tiling R, Schmidt M et al. High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system. Invest Radiol 2005;40:743-53. (Pubitemid 41690430)
62. Schlemmer HP, Schafer J, Pfannenberg C, Radny P, Korchidi S, Muller-Horvat C et al. Fast whole-body assessment of metastatic disease using a novel magnetic resonance imaging system: initial experiences. Invest Radiol 2005;40:64-71. (Pubitemid 40144410)
63. Schmidt GP, Reiser MF, Baur-Melnyk A. Whole-body MRI for the staging and follow-up of patients with metastasis. Eur J Radiol 2009;70:393-400.
64. Quick HH, von Gall C, Zeilinger M, Wiesmuller M, Braun H, Ziegler S et al. Integrated whole-body PET/MR hybrid imaging: clinical experience. Invest Radiol 2013;48:280-9.
65. Kjaer A, Loft A, Law I, Berthelsen AK, Borgwardt L, Lofgren J et al. PET/MRI in cancer patients: first experiences and vision from Copenhagen. MAGMA 2013;26:37-47.
66. Schmidt GP, Baur-Melnyk A, Haug A, Heinemann V, Bauerfeind I, Reiser MF et al. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT. Eur J Radiol 2008;65:47-58.
67. Antoch G, Vogt FM, Freudenberg LS, Nazaradeh F, Goehde SC, Barkhausen J et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 2003;290:3199-206. (Pubitemid 38020681)
68. Frericks BB, Meyer BC, Martus P, Wendt M, Wolf KJ, Wacker F. MRI of the thorax during whole-body MRI: evaluation of different MR sequences and comparison to thoracic multidetector computed tomography (MDCT). J Magn Reson Imaging 2008;27:538-45. (Pubitemid 351354738)
69. Semelka RC, Martin DR, Balci C, Lance T. Focal liver lesions: comparison of dual-phase CT and multisequence multiplanar MR imaging including dynamic gadolinium enhancement. J Magn Reson Imaging 2001;13:397-401. (Pubitemid 32173407)
70. Bauerle T, Hilbig H, Bartling S, Kiessling F, Kersten A, Schmitt-Graff A et al. Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI. Neoplasia 2008;10:511-20. (Pubitemid 351657393)
71. Ghanem N, Uhl M, Brink I, Schafer O, Kelly T, Moser E et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol 2005;55:41-55. (Pubitemid 40798487)
72. Altehoefer C, Ghanem N, Hogerle S, Moser E, Langer M. Comparative detectability of bone metastases and impact on therapy of magnetic resonance imaging and bone scintigraphy in patients with breast cancer. Eur J Radiol 2001;40:16-23. (Pubitemid 32982905)
73. Engelhard K, Hollenbach HP, Wohlfart K, von Imhoff E, Fellner FA. Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer. Eur Radiol 2004;14:99-105. (Pubitemid 38181060)
74. Liu T, Cheng T, Xu W, Yan WL, Liu J, Yang HL. A meta-analysis of 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer. Skeletal Radiol 2011;40:523-31.
75. Schmidt GP, Schoenberg SO, Schmid R, Stahl R, Tiling R, Becker CR et al. Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 2007;17:939-49. (Pubitemid 46766875)
76. Daldrup-Link HE, Franzius C, Link TM, Laukamp D, Sciuk J, Jurgens H et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 2001;177:229-36. (Pubitemid 32578088)
77. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007;188:1622-35. (Pubitemid 46866868)
78. Marini C, Iacconi C, Giannelli M, Cilotti A, Moretti M, Bartolozzi C. Quantitative diffusion-weighted MR imaging in the differential diagnosis of breast lesion. Eur Radiol 2007;17:2646-55.
79. Kamitani T, Hatakenaka M, Yabuuchi H, Matsuo Y, Fujita N, Jinnouchi M et al. Detection of axillary node metastasis using diffusion-weighted MRI in breast cancer. Clin Imaging 2013;37:56-61.
80. Szafer A, Zhong J, Anderson AW, Gore JC. Diffusion-weighted imaging in tissues: theoretical models. NMR Biomed 1995;8:289-96.
81. Heusner TA, Kuemmel S, Koeninger A, Hamami ME, Hahn S, Quinsten A et al. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging 2010;37:1077-86.
82. Qayyum A. Diffusion-weighted imaging in the abdomen and pelvis: concepts and applications. Radiographics 2009;29:1797-810.
83. Grankvist J, Fisker R, Iyer V, Frund ET, Simonsen C, Christensen T et al. MRI and PET/CT of patients with bone metastases from breast carcinoma. Eur J Radiol 2012;81:e13-8.
84. Balyasnikova S, Lofgren J, de Nijs R, Zamogilnaya Y, Hojgaard L, Fischer BM. PET/MR in oncology: an introduction with focus on MR and future perspectives for hybrid imaging. Am J Nucl Med Mol Imaging 2012;2:458-74.
85. Montemurro F, Russo F, Martincich L, Cirillo S, Gatti M, Aglietta M et al. Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy. Acta Radiol 2004;45:71-4.
86. Jackson A, O'Connor JP, Parker GJ, Jayson GC. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 2007;13:3449-59. (Pubitemid 46955104)
87. Dehdashti F, Laforest R, Gao F, Aft RL, Dence CS, Zhou D et al. Assessment of progesterone receptors in breast carcinoma by PET with 21-18F-fluoro-16alpha,17alpha-[(R)-(1′-alpha-furylmethylidene)dioxy] -19-norpregn-4-ene-3,20-dione. J Nucl Med 2012;53:363-70.
88. Goldhirsch A, Colleoni M, Gelber RD. Endocrine therapy of breast cancer. Ann Biol 2002;13 Suppl 4:61-8. (Pubitemid 35369974)
89. van Kruchten M, Glaudemans AW, de Vries EF, Beets-Tan RG, Schroder CP, Dierckx RA et al. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. J Nucl Med 2012;53:182-90.
90. Santinelli A, Pisa E, Stramazzotti D, Fabris G. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer 2008;122:999-1004. (Pubitemid 351213996)
91. Broom RJ, Tang PA, Simmons C, Bordeleau L, Mulligan AM, O'Malley FP et al. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res 2009;29:1557-62.
92. Chung GG, Zerkowski MP, Ghosh S, Camp RL, Rimm DL. Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Lab Invest 2007;87:662-9. (Pubitemid 46920099)
93. Hospers GA, Helmond FA, de Vries EG, Dierckx RA, de Vries EF. PET imaging of steroid receptor expression in breast and prostate cancer. Curr Pharm Des 2008;14:3020-32.
94. Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Biol 2006;24:2793-9. (Pubitemid 46630578)
95. McGuire WL, Chamness GC, Fuqua SA. Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 1991;5:1571-7.
96. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010;87:586-92.
97. Gaykema SB, Brouwers AH, Hovenga S, Lub-de Hooge MN, de Vries EG, Schroder CP. Zirconium-89-trastuzumab positron emission tomography as a tool to solve a clinical dilemma in a patient with breast cancer. J Clin Biol 2012;30:e74-5.
98. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998;4:1334-6. (Pubitemid 28512118)
99. Bading JR, Shields AF. Imaging of cell proliferation: status and prospects. J Nucl Med 2008;49 Suppl 2:64S-80S. (Pubitemid 351948037)
100. Smyczek-Gargya B, Fersis N, Dittmann H, Vogel U, Reischl G, Machulla HJ et al. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 2004;31:720-4. (Pubitemid 38647912)
101. Kenny LM, Vigushin DM, Al-Nahhas A, Osman S, Luthra SK, Shousha S et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res 2005;65:10104-12. (Pubitemid 41541493)
102. Been LB, Elsinga PH, de Vries J, Cobben DC, Jager PL, Hoekstra HJ et al. Positron emission tomography in patients with breast cancer using (18)F-3′-deoxy-3′-fluoro-l-thymidine ((18)F-FLT)-a pilot study. Eur J Surg Biol 2006;32:39-43. (Pubitemid 43103986)
103. Pio BS, Park CK, Pietras R, Hsueh WA, Satyamurthy N, Pegram MD et al. Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 2006;8:36-42. (Pubitemid 44201576)
104. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F] fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 2007;34:1339-47. (Pubitemid 47312585)
105. Contractor KB, Kenny LM, Stebbing J, Rosso L, Ahmad R, Jacob J et al. [18F]-3′Deoxy-3′-fluorothymidine positron emission tomography and breast cancer response to docetaxel. Clin Cancer Res 2011;17:7664-72.
106. Contractor K, Aboagye EO, Jacob J, Challapalli A, Coombes RC, Stebbing J. Monitoring early response to taxane therapy in advanced breast cancer with circulating tumor cells and [(18)F] 3 -deoxy-3 -fluorothymidine PET: a pilot study. Biomark Med 2012;6:231-3.
107. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
108. Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 2006;11:753-64. (Pubitemid 44157563)
109. Gilbert MR, Kuhn J, Lamborn KR, Lieberman F, Wen PY, Mehta M et al. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol 2012;106:147-53.
110. Beer AJ, Niemeyer M, Carlsen J, Sarbia M, Nahrig J, Watzlowik P et al. Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. J Nucl Med 2008;49:255-9. (Pubitemid 351225664)
111. Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL et al. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 2006;12:3942-9. (Pubitemid 44078079)
112. Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA 1994;271:1593-7. (Pubitemid 24155619)